Genentech, a subsidiary of Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), announced that its thrombolytic agent TNKase (tenecteplase) has been approved by the US Food and Drug Administration (FDA) for the treatment of acute ischemic stroke (AIS) in adults.
Drug Profile
TNKase, a tissue plasminogen activator, is administered as a single five-second intravenous bolus. This is faster and simpler than the standard-of-care, Activase, which requires an IV bolus followed by a 60 – minute infusion. The new 25 mg vial configuration of TNKase is expected to be introduced in the next few months, facilitating its use in AIS treatment.-Fineline Info & Tech
